Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I, Open-Label, Multi-Centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML).

Next Previous
Trial Profile

A Phase I, Open-Label, Multi-Centre, Multiple Ascending Dose Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) in Patients With Acute Myeloid Leukaemia (AML).

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Barasertib (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions
  • Sponsors AstraZeneca

Most Recent Events

  • 03 Mar 2011 Planned End Date changed from 1 Feb 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
  • 09 Dec 2010 Planned End Date changed from 1 Dec 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
  • 06 Oct 2010 New source identified and integrated (M.D. Anderson Cancer Center, 2009-0172).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top